Voyager Therapeutics Announces New Data at the American Society of Gene and Cell Therapy 2018 Annual Meeting
17 mai 2018 18h15 HE
|
Voyager Therapeutics, Inc.
VY-SOD101 achieves meaningful suppression of disease-causing gene of ALS in large mammals after a one-time administration Results during the second half of 2018 from further delivery optimization...
Voyager Therapeutics Announces First Quarter 2018 Financial Results and Corporate Highlights
10 mai 2018 07h04 HE
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., May 10, 2018 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe...
Wave Life Sciences and Takeda Form Global Strategic Collaboration to Advance Therapies for Central Nervous System Disorders
20 févr. 2018 07h00 HE
|
Wave Life Sciences
Wave to receive at least $230 million, including $110 million in upfront cash, $60 million in equity investment and at least $60 million in research support Takeda to receive option to co-develop...
Vaccinex, Inc. to Host Key Opinion Leader Luncheon on Huntington’s Disease
30 janv. 2018 11h14 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., Jan. 30, 2018 (GLOBE NEWSWIRE) -- Vaccinex, Inc., a privately-held clinical-stage biotechnology company engaged in the discovery and development of human therapeutic monoclonal...
Emerald Health Therapeutics’ Scientific Advisors Publish Research Discovery of THCA Cannabinoid’s Neuroprotective Treatment Potential
20 sept. 2017 07h00 HE
|
Emerald Health Therapeutics Inc.
VICTORIA, British Columbia, Sept. 20, 2017 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics Inc. (EHT) (TSXV:EMH) (OCTQX:EMHTF), a Canadian licensed medical producer of cannabis, is pleased to report...
Voyager Therapeutics Reports Second Quarter 2017 Financial Results and Corporate Highlights
08 août 2017 07h05 HE
|
Voyager Therapeutics
CAMBRIDGE, Mass., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe neurological...
Voyager Therapeutics Selects Lead Clinical Candidate for Huntington’s Disease
01 juin 2017 07h04 HE
|
Voyager Therapeutics
CAMBRIDGE, Mass., June 01, 2017 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe neurological...
Voyager Therapeutics and CHDI Foundation Collaborate to Develop Novel Gene Therapy for Huntington’s Disease
12 sept. 2016 07h05 HE
|
Voyager Therapeutics
CAMBRIDGE, Mass., Sept. 12, 2016 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the...
Raptor Pharmaceutical Presents Results from Meta-Analysis Demonstrating Efficacy of QUINSAIR™ Comparable to Other Approved, Inhaled Antibiotics in Cystic Fibrosis Patients
07 sept. 2016 03h30 HE
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Sept. 07, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP), a biopharmaceutical company developing and commercializing transformative treatments for rare diseases,...
Raptor Pharmaceutical to Present Data on QUINSAIR™ and Other Inhaled Antibiotics at the ERS International Congress
24 août 2016 07h30 HE
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Aug. 24, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP), a biopharmaceutical company developing and commercializing transformative treatments for rare diseases,...